Paul Geevarghese, COO and Co-Founder of 9amHealth, stated in the news release announcing the partnernship, "We're not only lowering the cost of medications, we're also connecting members to real, human care: specialists in obesity and diabetes, clinical pharmacists, and ongoing nutritional support with registered dietitiansall from the comfort of home." Adding to that thought, Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, said, "At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with clinical leaders in obesity like 9amHealth, we are dedicated to providing affordable and accessible healthcare solutions for patients with cardiometabolic conditions." What We Don't Know
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future
still appropriate for patients not on CGM, especially on insulin Inpatient Diabetes Management Per ADA 2026 Section 16 (Diabetes Care in the Hospital), insulin is the preferred agent for managing hyperglycemia in hospitalized patients (target BG 140180 mg/dL per ICU guidelines
Ahead of the trial, they were invited to drink their preferred alcoholic beverages over a two-hour period in a comfortable setting
